X

Drug Profile

Research programme: eye disorder therapeutics - Kamat Pharmatech

Latest Information Update: 26 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kamat Pharmatech
Class Anti-inflammatories; Ciclosporins
Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Dry eyes; Inflammation

Most Recent Events

26 Sep 2023 Discontinued - Preclinical for Dry eyes in USA (Ophthalmic)
26 Sep 2023 Discontinued - Preclinical for Inflammation in USA (Ophthalmic)
28 Dec 2020 No recent reports of development identified for preclinical development in Dry-eyes in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com